Acrivon Therapeutics, Inc. (ACRV)
$8.08
+0.02
(+0.25%)▲
Performance
- $8.00$8.34$8.08
0.99%
Downside
Day's Volatility :4.08%
Upside
3.12%
- $3.19$11.90$8.08
60.52%
Downside
52 Weeks Volatility :73.19%
Upside
32.1%
Returns
| Period | Acrivon Therapeutics, Inc. | Index (Russel 2000) |
|---|---|---|
3 Months | 11.45% | 0.0% |
6 Months | 57.5% | 0.0% |
1 Year | -30.94% | 0.0% |
3 Years | -51.44% | -22.3% |
Highlights
Market Capitalization | 249.6M |
Book Value | $6.98 |
Earnings Per Share (EPS) | -2.72 |
Wall Street Target Price | 22.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -24.41% |
Return On Equity TTM | -37.78% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -75.6M |
Diluted Eps TTM | -2.72 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.43 |
EPS Estimate Next Year | -2.7 |
EPS Estimate Current Quarter | -0.6 |
EPS Estimate Next Quarter | -0.57 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 172.28%
Technicals Summary
Sell
Neutral
Buy
Acrivon Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Acrivon Therapeutics, Inc. | 15.59% | 57.5% | -30.94% | -51.44% | -51.44% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Acrivon Therapeutics, Inc. | NA | NA | NA | -2.43 | -0.38 | -0.24 | NA | 6.98 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Acrivon Therapeutics, Inc. | Buy | $249.6M | -51.44% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Acrivon Therapeutics, Inc.
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 68.0%
Institutional Holdings
RA Capital Management, LLC
26.93%Perceptive Advisors LLC
17.31%Sands Capital Ventures, LLC
6.85%Marshall Wace Asset Management Ltd
3.06%Wellington Management Company LLP
2.87%BlackRock Inc
2.48%
Company Information
acrivon therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. the foundational science is based on proven, pathway-based methods linking active disease-driving mechanisms with the drug mechanism-of-action, to precisely match the therapy with patients who will benefit. our method is applicable across drug modalities
Organization | Acrivon Therapeutics, Inc. |
Employees | 58 |
CEO | Dr. Peter Blume-Jensen M.D., Ph.D. |
Industry | Healthcare |
